Overview
A National Coverage Determination (NCD) is a CMS-issued, nationwide Medicare coverage decision that specifies whether a specific service, item, device, or procedure is covered under Medicare, and if covered, the clinical indications, beneficiary criteria, and documentation required. NCDs apply uniformly to Medicare Parts A and B across all jurisdictions and are binding on all Medicare Administrative Contractors (MACs), Medicare Advantage plans, and Part D plans where applicable.
NCDs are issued through a formal National Coverage Analysis (NCA) process. CMS initiates an NCA based on internal request, external request (from beneficiaries, providers, manufacturers, professional societies), or agency-identified need. The process involves evidence review by CMS and its contractor Coverage and Analysis Group, a public comment period, proposed decision memorandum, additional public comment, and final decision memorandum. NCAs typically take 6–12 months from initiation to final decision. Complex technology assessments may invoke Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) input.
NCDs take several forms: (1) unconditional coverage — covered without specific limitations; (2) coverage with evidence development (CED) — covered only when the service is delivered in the context of a specified clinical study or registry; (3) coverage with specific clinical criteria — covered only for specified beneficiary populations or clinical conditions; (4) non-coverage — explicitly not covered. CED decisions, introduced via the CED framework, allow Medicare to cover emerging technologies while requiring evidence collection that can inform future full-coverage decisions.
For RCM, NCDs drive hard coverage edits. Unlike LCDs (which vary by jurisdiction), NCDs produce uniform coverage rules across all Medicare lines of business. Claim scrubbers and clearinghouse edits reject claims submitted outside NCD criteria. The NCD-specified ICD-10-CM codes, CPT/HCPCS codes, frequency limits, and site-of-service restrictions directly feed into medical-necessity edit libraries. Beneficiary notification via ABN applies when a service is likely to be denied under NCD criteria.
Recent high-profile NCDs illustrate the scope. The 2022 Aduhelm NCD restricted Medicare coverage of monoclonal antibodies targeting amyloid for Alzheimer's disease to CMS-approved clinical trials — a coverage-with-evidence-development decision that substantially limited access. The 2016 MRA for vertebral augmentation; the 2007 Implantable Cardioverter Defibrillators NCD with its detailed clinical criteria; the evolving Cardiac Rehabilitation coverage — these shape billing workflows for entire specialties.
NCDs can be appealed through the standard Medicare appeals process and through requests for reconsideration of the NCD itself. The Medicare Coverage Database (MCD) publishes all NCDs with full decision memoranda. Providers should monitor the CMS MCD and the Federal Register for NCD-related activity that affects their specialty. Specialty societies (ACC, ACR, ACS, AUA, and others) typically submit reconsideration requests and provide clinical evidence to shape NCD outcomes.
Industry benchmark
Social Security Act §1862(a)(1). Medicare Program Integrity Manual Chapter 13. 42 CFR §405.1060. CMS Medicare Coverage Database.
Worked example
The NCD for Implantable Cardioverter Defibrillators (ICDs) for primary prevention specifies detailed clinical criteria: LVEF ≤35%, NYHA Class II–III heart failure, optimal medical therapy for 3+ months post-MI or 40+ days post-revascularization, and life expectancy >1 year. A hospital bills ICD implantation for a patient with LVEF 40% (outside criteria). The claim denies under NCD; the provider cannot bill the beneficiary without an ABN. Proper NCD-driven pre-authorization prevents these denials.
Frequently asked questions — National Coverage Determination (NCD)
How does an NCD differ from an LCD?
NCDs are nationwide CMS coverage decisions binding on all MACs. LCDs are MAC-specific and apply only in that jurisdiction. NCDs control when both exist; LCDs fill gaps where no NCD exists and may add local implementation detail without conflicting with the NCD.
What is Coverage with Evidence Development (CED)?
CED allows Medicare to cover emerging technologies conditionally — only when the service is delivered within a CMS-approved clinical study or registry. Coverage is limited and evidence-collection is required. The Aduhelm NCD is a recent CED example.
How long does an NCA take?
Typically 6–12 months from initiation to final decision, including public comment periods. Complex technology assessments involving MEDCAC review can extend the timeline. The process is published on the CMS Medicare Coverage Database in real time.
Can providers appeal NCD decisions?
Individual claim denials can be appealed through the standard five-level Medicare appeal process. The NCD itself can be challenged through a reconsideration request (requires new evidence) or through a complaint in federal court, though courts defer heavily to CMS on coverage policy.
Disclaimer
This glossary entry is operational reference for revenue-cycle and medical-billing professionals. It is not legal, clinical, or contractual advice. Industry benchmarks cite named public sources where available; always verify against the current guidance from the authority body before relying on a number in a contract, policy, or compliance filing.